[1] Jiang H, Wei C. How to address vaccine hesitancy? Lessons from national hepatitis B immunization program in China[J]. Front Public Health, 2024,12:1286801.
[2] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023,36(01):1-17.
[3] Zhang P, Tang Q, Zhu J, et al. Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis[J]. Hepatol Int, 2024,18(4):1110-1121.
[4] Meier M, Calabrese D, Suslov A, et al. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load[J]. J Hepatol, 2021,75(4):840-847.
[5] Hsu Y, Jun D W, Peng C, et al. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort[J]. Hepatol Int, 2022,16(6):1297-1307.
[6] Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J]. Dig Dis Sci, 2015,60(5):1457-1464.
[7] 鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021,37(06):1268-1274.
[8] Bsisu I, Rmilah A A. Global elimination of chronic hepatitis[J]. N Engl J Med, 2019,381(6):589.
[9] Pockros P J, Mulgaonkar A. Cessation of nucleoside/nucleotide analogue therapy in chronic hepatitis B HBeAg-negative patients[J]. Gastroenterol Hepatol (N Y), 2022,18(6):320-325.
[10] Hadziyannis S J, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir[J]. Gastroenterology, 2012,143(3):629-636.
[11] van Bommel F, Berg T. Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B[J]. Hepatol Commun, 2021,5(10):1632-1648.
[12] Berg T, Simon K, Mauss S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study[J]. J Hepatol, 2017,67(5):918-924.
[13] Hirode G, Choi H S J, Chen C, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)[J]. Gastroenterology, 2022,162(3):757-771.
[14] Wang J, Zhu L, Zhang S, et al. Clinical outcomes of treatment-naive HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA[J]. Emerg Microbes Infect, 2024,13(1):2339944.
[15] 朱鹏, 唐怡. 《亚太肝病学会乙型肝炎管理的临床实践指南(2015年更新)》推荐意见[J]. 临床肝胆病杂志, 2016,32(3):423-428.
[16] Berg T, Lampertico P. The times they are a-changing - a refined proposal for finite HBV nucleos(t)ide analogue therapy[J]. J Hepatol, 2021,75(2):474-480.
[17] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017,67(2):370-398.
[18] Terrault N A, Lok A S F, McMahon B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018,67(4):1560-1599.
[19] EASL Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2025.
[20] 鲁凤民, 于乐成, 高林, 等. HBeAg阴性慢性乙型肝炎患者停药后HBsAg可阴转:停药-治愈策略或许正在来临[J]. 中华医学杂志, 2022,102(40):3160-3166.
[21] Benechet A P, De Simone G, Di Lucia P, et al. Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming[J]. Nature, 2019,574(7777):200-205.
[22] Garcia-Lopez M, Lens S, Pallett L J, et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients[J]. J Hepatol, 2021,74(5):1064-1074.
[23] Tseng T, Cheng H, Su T, et al. Higher hepatitis B core-specific T cell response is associated with a lower risk of clinical relapse after discontinuation of oral antiviral treatment[J]. J Microbiol Immunol Infect, 2024,57(5):700-708.
[24] Li Y, Wen C, Gu S, et al. Differential response of HBV envelope-specific CD4 + T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy[J]. Hepatology, 2023,78(2):592-606.
[25] Zimmer C L, Rinker F, Honer Zu Siederdissen C, et al. Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss[J]. J Infect Dis, 2018,217(10):1656-1666.
[26] Peppa D, Micco L, Javaid A, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection[J]. PLoS Pathog, 2010,6(12):e1001227.
[27] Islam M, Kumar K, Sevak J K, et al. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN[J]. Hepatol Commun, 2023,7(5).
[28] Rivino L, Le Bert N, Gill U S, et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation[J]. J Clin Invest, 2018,128(2):668-681.
[29] Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection[J]. PLoS Pathog, 2014,10(1):e1003856.
[30] Barnes E. Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis[J]. J Clin Invest, 2018,128(2):573-576.
[31] Rinker F, Zimmer C L, Honer Zu Siederdissen C, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B[J]. J Hepatol, 2018,69(3):584-593. |
